Multiple Myeloma Research Foundation (MMRF), Amgen, Adaptive Biotechnologies, University of Turin deal

The partners will perform sequencing-based assessment of minimal residual disease (MRD) on more than 400 patients with multiple myeloma (MM) enrolled in the open-label Phase II INSIDE MM-1 trial of K...